Naïve averaged, naïve pooled, and population pharmacokinetics of orally administered marbofloxacin in juvenile harbor seals

Journal of the American Veterinary Medical Association

Volumn 230, Issue 3, 2007, Pages 390-395

  KuKanich, Butch ^a,e   Huff, David ^c,d   Riviere, Jim E ^b   Papich, Mark G ^a  

^a Department of Molecular Biomedical Sciences ^*

^b Center for Chemical Toxicology Research and Pharmaco Kinetics

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d VANCOUVER AQUARIUM   (Canada)

^e KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENZYME INHIBITOR; MARBOFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLIC CLEARANCE RATE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PHOCA;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; FLUOROQUINOLONES; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHOCA; QUINOLONES;

ANIMALIA; BACTERIA (MICROORGANISMS); PHOCA; PHOCA VITULINA; PSEUDOMONAS AERUGINOSA;

EID: 33846853539     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.230.3.390     Document Type: Article

References (19)

1. Spreng M, Deleforge J, Thomas V, et al. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates.; Vet Phamacol Ther 1995;18:284-289.
2. Riddle C, Lemons CL, Papich MG, et al. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. J Clin Microbiol 2000;38:1636-1637.
3. Schneider M, Thomas V, Boisrame B, et al. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration. J Vet Pharmacol Ther 1996;19:56-61.
4. Frazier DL, Thompson L, Trettien A, et al. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J Vet Pharmacol Ther 2000;23:293-302.
5. Bousquet-Melou A, Bernard S, Schneider M, et al. Pharmacokinetics of marbofloxacin in horses. Equine Vet J 2002;34:366-372.
6. Waxman S, Rodriguez C, Gonzalez F, et al. Pharmacokinetic behav ior of marbofloxacin after intravenous and intramuscular administrations in adult goats. J Vet Pharmacol Ther 2001;24:375-378.
7. Aliabadi FS, Lees E Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. J Vet Pharmacol Ther 2002;25: 161-174.
8. Dudley MN. Pharmacokinetics and pharmacodynamics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991;91:45S-50S.
9. Lees P, Concordet D, Aliabadi FS, et al. Drug selection and optimization of dosage schedules to minimize antimicrobial resistance. In: Aarestrup FM, ed. Antimicrobial resistance in bacteria of animal origin. Washington, DC: ASM Press, 2006;49-71.
10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998:26:1-12.
11. Lacy MK, Lu W, Xu X, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999;43:672-677.
12. Riviere JE. Population pharmacokinetic models and Bayesian forecasting applied to clinical pharmacokinetics. In: Comparative pharmacokinetics: principles, techniques, and applications. Ames, Iowa: Iowa State University Press, 1999;259-282.
13. Martin-Jimenez T, Papich MG, Riviere JE. Population pharmacokinetics of gentamicin in horses. Am J Vet Res 1998;59:1589-1598.
14. Craigmill AL, Holland RE, Robinson D, et al. Serum pharmacokinetics of oxytetracycline in sheep and calves and tissue residues in sheep following a single intramuscular injection of a long-acting preparation. J Vet Pharmacol Ther 2000;23:345-352.
15. Benson KG, Tell LA, Young LA, et al. Pharmacokinetics of ceftiofur sodium after intramuscular or subcutaneous administration in green iguanas (Iguana iguana). Am J Vet Res 2003;64:1278-1282.
16. Osofsky A, Tell LA, Kass PH, et al. Investigation of Japanese quail (Coturnix japonica) as a pharmacokinetic model for cockatiels (Nymphicus hollandicus) and Poicephalus parrots via comparison of the pharmacokinetics of a single intravenous injection of oxytetracycline hydrochloride. J Vet Pharmacol Ther 2005;28:505-513.
17. Bidgood TL, Papich MG. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and constant intravenous infusion in dogs J Vet Pharmacol Ther 2005;28:329-341.
18. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;1-494.
19. Lefebvre HP, Schneider M, Dupouy V, et al. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J Vet Pharmacol Ther 1998;21:453-461.